Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous triptorelin 6-month formulation in previously castrated advanced prostate cancer
NL-OMON53969Phase 3Completed
- Sponsor
- Ipsen
- Start
- Nov 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of triptorelin in prostate cancer (PCa) and prostate adenocarcinoma, sponsored by Ipsen. Primary endpoint: Primary efficacy endpoint. Started Nov 2022; status: completed.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on NL-OMON53969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53969.